Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients

Aims: Under- and, especially, overdosing of replacement therapy in haemophilia A patients may be prevented by application of other morphometric variables than body weight (BW) to dose factor VIII (FVIII) concentrates. Therefore, we aimed to investigate which morphometric variables best describe interindividual variability (IIV) of FVIII concentrate pharmacokinetic (PK) parameters. Methods: PK profiling was performed by measuring 3 FVIII levels after a standardized dose of 50 IU kg−1 FVIII concentrate. A populat

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

Essentials Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery. We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels. Population PK parameter values for clearance and V1 were 284 mL h−170 kg−1 and 5450 mL70 kg−1. Perioperative PK parameters differ from those during non-surgical prophylactic treatment. Summary: Background Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative sett

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients

Introduction: Many patients with von Willebrand disease (VWD) are treated on demand with von Willebrand factor and factor VIII (FVIII) containing concentrates present with VWF and/or FVIII plasma levels outside set target levels. This carries a risk for bleeding and potentially for thrombosis. Development of a population pharmacokinetic (PK) model based on FVIII levels is a first step to more accurate on-demand perioperative dosing of this concentrate

Emotions in consumer research: An application to novel food products

During the last decades the general public has been confronted with a continuous stream of radically new food products as well as technologies that can be used to improve food production and food products. It is rather difficult, however, to convince consumers to accept these new products. For instance, the majority of consumers reject genetically modified food products completely. When consumers are interested or even concerned about the production of food products, their emotions with respect to a particular food product will be sparked. This dissertation concentrates on the causes and consequences of consumer emotions for different new food products in four projects. The first project lays the groundwork by discussing the structure and content of consumer emotions, and unites seemingly diverging research streams into one framework. In the other three projects consumer emotions associated with novel food products (genetically modified food and functional food) are embedded in frameworks including their antecedents and consequences

Emotions in Consumer Research: An Application to Novel Food Products.

During the last decades the general public has been confronted with a continuous stream of radically new food products as well as technologies that can be used to improve food production and food products. It is rather difficult, however, to convince consumers to accept these new products. For instance, the majority of consumers reject genetically modified food products completely. When consumers are interested or even concerned about the production of food products, their emotions with respect to a particular food product will be sparked. This dissertation concentrates on the causes and consequences of consumer emotions for different new food products in four projects. The first project lays the groundwork by discussing the structure and content of consumer emotions, and unites seemingly diverging research streams into one framework. In the other three projects consumer emotions associated with novel food products (genetically modified food and functional food) are embedded in frameworks including their antecedents and consequences.

Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications

Thrombosis and Hemostasi